PDSS2

PDSS2 encodes a catalytic subunit of decaprenyl diphosphate synthase, the first committed enzyme of the CoQ10 biosynthetic pathway, and its loss-of-function reduces cellular coenzyme Q and impairs mitochondrial respiratory chain function (PMID:17186472, PMID:29967258). Compound heterozygous PDSS2 mutations abolish decaprenyl diphosphate synthase activity in patient fibroblasts, establishing PDSS2 as a cause of human CoQ deficiency (PMID:17186472). In mouse models, CoQ9 deficiency produces respiratory chain abnormalities with organ-selective consequences: kidney-specific oxidative stress drives mitochondrial DNA depletion, loss of mitochondrial mass, and renal failure, whereas neuronal Pdss2 loss impairs cerebellar development, causes progressive Purkinje and dopaminergic neuron loss, and produces ataxia and neuromuscular deficits (PMID:23150520, PMID:21871565, PMID:21983691). Restoring full-length PDSS2 raises CoQ10 and complex I activity and shifts cells from aerobic glycolysis to mitochondrial respiration, and PDSS2 loss induces chromosomal instability and malignant transformation, defining a tumor-suppressive role in hepatocellular carcinoma (PMID:29967258). PDSS2 tumor suppression is partly non-enzymatic: catalytic-dead PDSS2 mutants retain growth- and motility-suppressing activity in lung cancer cells (PMID:36860919). PDSS2 transcription is repressed by Sp1 binding the proximal promoter and by an SKA2–Sp1 complex, and cis-regulatory variation alters its output (PMID:31783675, PMID:36860919, PMID:25166907). PDSS2 also engages the Nrf2 antioxidant pathway to limit ROS, iron accumulation, and ferroptosis in vascular endothelial cells (PMID:33929387). In contrast, the exon-2-deleted splice variant PDSS2-Del2, which lacks CoQ10 biosynthetic activity, promotes metastasis by depleting fumarate and activating NF-κB, and by driving SKOR1 degradation, SMAD3 phosphorylation, and MST1-dependent M2 macrophage polarization (PMID:33064899, PMID:39695147).

1. 2006 High

   Established that PDSS2 is a catalytic subunit of decaprenyl diphosphate synthase and that its mutation causes human CoQ10 deficiency, defining the gene's enzymatic identity and disease relevance.

   Evidence Radiolabeled-substrate enzymatic assays in patient fibroblasts plus genetic identification of compound heterozygous mutations

   PMID:17186472

   Open questions at the time

   • Does not resolve the structure or stoichiometry of the synthase complex
   • Subunit partner(s) of PDSS2 in the synthase not defined in this finding
2. 2011 High

   Connected PDSS2/CoQ deficiency to organ-specific pathology, showing tissue-restricted consequences in kidney podocytes and across distinct neuronal populations rather than a uniform respiratory collapse.

   Evidence Conditional knockout mouse models (podocyte, Pax2-cre cerebellar, Pcp2-cre Purkinje, dopaminergic) with histology, CoQ9 measurement, pharmacological probucol rescue, and behavioral assays

   PMID:21567994 PMID:21871565 PMID:21983691

   Open questions at the time

   • Mechanism of organ selectivity of oxidative stress not fully defined
   • Dopaminergic phenotype from single lab with Medium confidence
   • Link between PPAR signaling normalization and CoQ restoration not mechanistically dissected
3. 2012 High

   Showed that CoQ9 deficiency triggers a defined oxidative-stress cascade — ROS, mtDNA depletion, and loss of mitochondrial mass — specifically in affected kidney, explaining how respiratory chain defects translate into organ failure.

   Evidence CBA/Pdss2 kd/kd mice profiled at multiple disease stages with ROS, oxidative damage markers, mtDNA quantification, and citrate synthase assays

   PMID:23150520

   Open questions at the time

   • Why kidney is selectively vulnerable to ROS unexplained
   • Causal ordering of mtDNA depletion versus mitochondrial loss not fully resolved
4. 2018 High

   Demonstrated that PDSS2 acts as a tumor suppressor in HCC by restoring CoQ10, complex I activity, and mitochondrial respiration, and that only full-length PDSS2 (not loss-of-function isoforms) retains this activity.

   Evidence Gain- and loss-of-function in HCC cell lines with CoQ10 and complex I assays, metabolic flux, soft-agar and xenograft tumor assays, chromosomal instability assays, and isoform-specific rescue

   PMID:29967258

   Open questions at the time

   • Whether tumor suppression is purely metabolic versus structural unresolved at this stage
   • Isoform comparison is Medium confidence from a single lab
5. 2019 High

   Defined the transcriptional control of PDSS2, identifying Sp1 as a direct promoter-bound repressor and mapping the core promoter, providing a mechanism for PDSS2 silencing.

   Evidence Luciferase reporter assays, site-directed mutagenesis of Sp1 sites, ChIP, Sp1 overexpression, and mithramycin A inhibition

   PMID:31783675

   Open questions at the time

   • Upstream signals controlling Sp1 occupancy at PDSS2 not identified
   • Co-repressors recruited with Sp1 not yet defined
6. 2020 Medium

   Revealed a gain-of-function for the CoQ-incompetent splice variant PDSS2-Del2, showing it actively promotes metastasis through fumarate depletion and NF-κB activation rather than simply lacking enzymatic activity.

   Evidence In vitro migration assays, xenograft and spleen-liver metastasis models, fumarate metabolite measurement, NF-κB reporter, and dimethyl fumarate rescue

   PMID:33064899

   Open questions at the time

   • Mechanism linking PDSS2-Del2 to fumarate metabolism not biochemically defined
   • Single-lab functional study
7. 2021 Medium

   Extended PDSS2 function to vascular biology, showing it engages the Nrf2 antioxidant pathway to suppress ROS, iron accumulation, and ferroptosis.

   Evidence ChIP and luciferase assays for Nrf2 interaction, overexpression/knockdown in HCAECs, ROS and iron assays, Nrf2-knockdown epistasis, and in vivo atherosclerosis model

   PMID:33929387

   Open questions at the time

   • Direct physical nature of the PDSS2–Nrf2 interaction not structurally confirmed
   • Single-lab study
   • Relationship to PDSS2 enzymatic activity in this context unclear
8. 2023 Medium

   Separated PDSS2 tumor suppression from its enzymatic activity by showing catalytic-dead mutants retain growth/motility suppression, and identified SKA2 as a Sp1-associated repressor of PDSS2.

   Evidence Co-IP of SKA2 with Sp1, luciferase reporter assays, PDSS2 catalytic-mutant rescue, growth/motility assays, and SKA2-knockdown expression profiling in lung cancer cells

   PMID:36860919

   Open questions at the time

   • Molecular basis of the non-enzymatic tumor-suppressive activity not identified
   • SKA2–Sp1 interaction rests on a single Co-IP
   • Effector proteins of catalytic-dead PDSS2 unknown
9. 2024 Medium

   Dissected a tumor-microenvironment mechanism for PDSS2-Del2, showing it drives SKOR1 ubiquitination/degradation, SMAD3 phosphorylation, and MST1-mediated M2 macrophage polarization that promotes HCC dissemination.

   Evidence Co-culture, ubiquitination assays, SMAD3 phospho-western, MST1 ELISA, macrophage polarization and PI3K/AKT analysis, and xenografts

   PMID:39695147

   Open questions at the time

   • Direct substrate-E3 relationship for SKOR1 degradation not defined
   • Single-lab study
   • How Del2 selectively activates this axis versus full-length PDSS2 unclear

• How a single locus reconciles an essential CoQ-biosynthetic enzyme, a non-enzymatic tumor suppressor, and an oncogenic metastasis-promoting splice variant — and what governs the splicing switch between these activities — remains unresolved.
• No structural model of PDSS2 or its catalytic-independent activity
• Regulation of PDSS2 vs PDSS2-Del2 splicing not defined
• Physical partners mediating non-enzymatic functions not mapped